Literature DB >> 32106831

GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy.

Shunsuke Ueki1,2, Fumiyoshi Fujishima3, Takuro Kumagai4, Hirotaka Ishida4, Hiroshi Okamoto4, Kai Takaya4, Chiaki Sato4, Yusuke Taniyma4, Takashi Kamei4, Hironobu Sasano3.   

Abstract

BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is a highly malignant neoplasm. The glucocorticoid (GC)-glucocorticoid receptor (GR) pathway plays pivotal roles in cellular response to various stresses of tumor cells, including chemotherapy. However, the status of the GC-GR pathway in ESCC, including its correlation with chemotherapeutic responses, is largely unknown.
METHODS: GR, serum-and glucocorticoid-regulated kinase 1 (Sgk1), and N-myc down regulation gene 1 (NDRG1) were immunolocalized in 98 patients with ESCC who had undergone esophagectomy following neoadjuvant chemotherapy (NAC) with 2 courses of 5-fluorouracil + cisplatin. We also examined biopsy specimens before NAC in 42 cases and compared the results between those before and after NAC.
RESULTS: Overall survival (OS) of the patients treated with surgery following NAC was significantly shorter in the group with high GR than that with low GR status (P = 0.0473). Both OS and disease-free survival (DFS) were significantly shorter in both Sgk1- and NDRG1-high groups than in the low groups (OS: Sgk1, P = 0.0055; NDRG1, P = 0.0021; DFS: Sgk1, P = 0.0240; NDRG1, P = 0.0086). Biopsy specimens before NAC showed significantly shorter DFS in the high Sgk1 group (P = 0.0095), while both OS and DFS were shorter in the high NDRG1 group (OS, P = 0.0233; DFS, P = 0.0006) than in the respective low groups. In the high NDRG1 group of biopsy specimens before NAC, the tumor reduction rate by NAC was significantly attenuated (P = 0.021).
CONCLUSIONS: High GR, Sgk1, and NDRG1 statuses in ESCC after NAC was significantly associated with an overall worse prognosis, with no significant changes in their expression levels before and after NAC. Therefore, increased activity of the GC-GR pathway with enhanced induction of Sgk1 and NDRG1 in carcinoma cells play pivotal roles in tumor progression and development of chemo-resistance in patients with ESCC undergoing NAC.

Entities:  

Keywords:  Chemo-resistance; Esophageal squamous cell carcinoma; Glucocorticoid receptor; NDRG1; Neoadjuvant chemotherapy; Sgk1

Year:  2020        PMID: 32106831     DOI: 10.1186/s12885-020-6652-7

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  9 in total

1.  Association between mitochondrial and nuclear DNA damages and cellular senescence in the patients with biliary atresia undergoing Kasai portoenterostomy and liver transplantation.

Authors:  Yudai Nakajima; Yuto Yamazaki; Xin Gao; Masatoshi Hashimoto; Masaki Nio; Motoshi Wada; Fumiyoshi Fujishima; Hironobu Sasano
Journal:  Med Mol Morphol       Date:  2022-03-03       Impact factor: 2.309

2.  Expression and clinicopathological significance of glucocorticoid receptor, SGK1, and NDRG1 in hormone-naïve prostate carcinoma.

Authors:  Shuko Hata; Hiroki Shimada; Naomi Sato; Mayu Koshiishi; Kazue Ise; Tomoaki Ogata; Shinichi Yamashita; Akihiro Ito; Hironobu Sasano; Yasuhiro Nakamura
Journal:  Med Mol Morphol       Date:  2022-07-21       Impact factor: 2.070

3.  Multifaceted and Intricate Oncogenic Mechanisms of NDRG1 in Head and Neck Cancer Depend on Its C-Terminal 3R-Motif.

Authors:  Guo-Rung You; Joseph T Chang; Hsiao-Fan Li; Ann-Joy Cheng
Journal:  Cells       Date:  2022-05-07       Impact factor: 7.666

4.  Correlation between TXNRD1/HO-1 expression and response to neoadjuvant chemoradiation therapy in patients with esophageal squamous cell carcinoma.

Authors:  Ryujiro Akaishi; Fumiyoshi Fujishima; Hirotaka Ishida; Junichi Tsunokake; Takuro Yamauchi; Yusuke Gokon; Shunsuke Ueki; Toshiaki Fukutomi; Hiroshi Okamoto; Kai Takaya; Chiaki Sato; Yusuke Taniyama; Tomohiro Nakamura; Naoki Nakaya; Takashi Kamei; Hironobu Sasano
Journal:  Esophagus       Date:  2022-01-08       Impact factor: 3.671

5.  Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-κB Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells.

Authors:  Masanobu Tsubaki; Tomoya Takeda; Takuya Matsuda; Shiori Seki; Yoshika Tomonari; Shoutaro Koizumi; Miki Nagatakiya; Mai Katsuyama; Yuuta Yamamoto; Katsumasa Tsurushima; Toshihiko Ishizaka; Shozo Nishida
Journal:  Biomedicines       Date:  2021-01-04

6.  Renal Injuries in Primary Aldosteronism: Quantitative Histopathological Analysis of 19 Patients With Primary Adosteronism.

Authors:  Hiroko Ogata; Yuto Yamazaki; Yuta Tezuka; Xin Gao; Kei Omata; Yoshikiyo Ono; Yoshihide Kawasaki; Tomoaki Tanaka; Hidekazu Nagano; Norio Wada; Yutaka Oki; Akira Ikeya; Kenji Oki; Yoshiyu Takeda; Mitsuhiro Kometani; Kazunori Kageyama; Ken Terui; Celso E Gomez-Sanchez; Shujun Liu; Ryo Morimoto; Kensuke Joh; Hiroshi Sato; Mariko Miyazaki; Akihiro Ito; Yoichi Arai; Yasuhiro Nakamura; Sadayoshi Ito; Fumitoshi Satoh; Hironobu Sasano
Journal:  Hypertension       Date:  2021-06-14       Impact factor: 9.897

7.  Expression Profiles of GILZ and SGK-1 in Potentially Malignant and Malignant Human Oral Lesions.

Authors:  Mahmood S Mozaffari; Rafik Abdelsayed
Journal:  Front Oral Health       Date:  2021-09-16

8.  The interaction of TEA domain transcription factor 4 (TEAD4) and Yes-associated protein 1 (YAP1) promoted the malignant process mediated by serum/glucocorticoid regulated kinase 1 (SGK1).

Authors:  Songlin He; Hanlu Zhang; Zongwei Xiao; Sandeep Bhushan; Ke Gao; Wenping Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

9.  HO-1 in lymph node metastasis predicted overall survival in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiation therapy.

Authors:  Ryujiro Akaishi; Fumiyoshi Fujishima; Hirotaka Ishida; Junichi Tsunokake; Takuro Yamauchi; Yusuke Gokon; Shunsuke Ueki; Toshiaki Fukutomi; Hiroshi Okamoto; Kai Takaya; Chiaki Sato; Yusuke Taniyama; Tomohiro Nakamura; Naoki Nakaya; Takashi Kamei; Hironobu Sasano
Journal:  Cancer Rep (Hoboken)       Date:  2021-07-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.